SCHEDULE: Alumni Capital Exits Kazia Therapeutics Stake

Alumni Capital LP and its affiliates have filed an exit statement, reporting zero beneficial ownership in Kazia Therapeutics Ltd. American Depository Shares.

Summary

• Alumni Capital LP, Alumni Capital GP LLC, and Ashkan Mapar (collectively, the "Reporting Persons") filed an Amendment No. 5 to Schedule 13G.
• The filing indicates that as of January 30, 2026, the Reporting Persons no longer beneficially own any American Depository Shares of Kazia Therapeutics Limited.
• This constitutes an "exit filing" for the Reporting Persons, signifying a complete divestment of their stake.
• The aggregate amount beneficially owned by each Reporting Person is 0.00, representing 0% of the class of securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal for Kazia Therapeutics, as a significant institutional investor has completely exited its position, potentially indicating a loss of confidence or a strategic shift away from the company.

Positives

• Alumni Capital LP, Alumni Capital GP LLC, and Ashkan Mapar have successfully completed their divestment of American Depository Shares in Kazia Therapeutics Limited.

Negatives

• An institutional investor, Alumni Capital LP, along with its affiliates, has fully divested its stake in Kazia Therapeutics Limited, reducing its beneficial ownership to 0%. This could be interpreted as a negative signal regarding the company's future prospects.

Future Outlook

No forward-looking statements or guidance regarding Kazia Therapeutics' future operations or financial performance are provided in this ownership disclosure.

Management Comments

• Ashkan Mapar, Manager of Alumni Capital GP LLC, General Partner of Alumni Capital LP, certified that the information set forth in the statement is true, complete, and correct to the best of his knowledge and belief.

Industry Context

StockSavvy.ai notes that institutional investors frequently adjust their positions in publicly traded companies, particularly in sectors like biotechnology where company prospects can evolve rapidly. An exit filing like this indicates a complete divestment by a previously disclosed significant holder, which can influence market perception.

Comparison to Industry Standards

• This filing primarily concerns a change in beneficial ownership by an institutional investor and does not contain operational or financial performance data for direct comparison to industry standards or specific competitors.

Stakeholder Impact

• Shareholders of Kazia Therapeutics may view the complete divestment by an institutional investor as a negative indicator, potentially impacting investor confidence and the company's stock price.

Key Dates

Recommendation

The complete divestment by Alumni Capital LP, an institutional investor, suggests a lack of conviction in Kazia Therapeutics' future prospects. This exit could put downward pressure on the stock price and indicates a potential negative sentiment from a sophisticated investor, warranting a sell recommendation.

Keywords

Kazia Therapeutics, Alumni Capital, Schedule 13G, exit filing, beneficial ownership, American Depository Shares, ADS, institutional investor